April Daniel
Family · Kingwood, TXNPI 1508479379
Payments from drug & device makers
Across 290 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$710
- AbbVie$618
- Novo Nordisk$532
- Lilly USA, LLC$464
- AstraZeneca$434
- Mylan Specialty L.p.$359
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,345100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 34 | $710 |
| AbbVie(2 entities) | 34 | $618 |
| Novo Nordisk | 36 | $532 |
| Lilly USA, LLC | 32 | $464 |
| AstraZeneca | 25 | $434 |
| Mylan Specialty L.p. | 15 | $359 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $289 |
| Boehringer Ingelheim | 10 | $185 |
| Astellas Pharma US Inc | 9 | $171 |
| Sumitomo Pharma America, Inc. | 9 | $165 |
| Sunovion Pharmaceuticals Inc. | 11 | $160 |
| Bayer | 9 | $156 |
| Dexcom, Inc. | 1 | $105 |
| Amgen | 2 | $104 |
| Medtronic | 1 | $103 |
| Johnson & Johnson | 5 | $78 |
| Pfizer | 3 | $69 |
| Biosense Webster, Inc. | 2 | $64 |
| Exact Sciences | 3 | $57 |
| Sanofi-aventis U.S. LLC | 4 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $50 |
| Antares Pharma, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Tolmar, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $35 |
| Tactile Systems Technology Inc | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Genentech USA, Inc. | 3 | $24 |
| Pacira Therapeutics, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $21 |
| Intuity Medical Inc | 1 | $20 |
| Impulse Dynamics (USA) Inc. | 1 | $19 |
| Philips North America LLC | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| G Medical Diagnostic Services, Inc. | 1 | $15 |
| Mission Pharmacal Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,345 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 121 | $170,050 |
| OzempicSemaglutide | 123 | $137,901 |
| TrulicityDulaglutide | 38 | $45,527 |
| JardianceEmpagliflozin | 37 | $41,362 |
| EliquisApixaban | 41 | $36,808 |
| FarxigaDapagliflozin Propanediol | 38 | $33,932 |
| XareltoRivaroxaban | 43 | $30,401 |
| GemtesaVibegron | 32 | $26,333 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $26,314 |
| EntrestoSacubitril/Valsartan | 20 | $24,475 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $18,161 |
| LinzessLinaclotide | 26 | $17,020 |
| JanuviaSitagliptin Phosphate | 14 | $13,713 |
| VascepaIcosapent Ethyl | 14 | $11,034 |
| TrintellixVortioxetine Hydrobromide | 11 | $8,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $464 | $215,577159 claims |
| Novo NordiskOzempic | $532 | $137,901123 claims |
| Boehringer IngelheimJardiance | $185 | $41,36237 claims |
| PfizerEliquis | $69 | $36,80841 claims |
| AstraZenecaFarxiga | $434 | $33,93238 claims |
| Johnson & JohnsonXarelto | $78 | $30,40143 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $165 | $26,33332 claims |
| AbbVieLinzess, Synthroid, Armour Thyroid | $618 | $20,38472 claims |
| GSKTrelegy Ellipta | $710 | $18,16122 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $25 | $8,87911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Kingwood
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.